ATAZANAVIR

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C38H52N6O7
Molecular Weight	704.8555
Optical Activity	( - )
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C

InChI

InChIKey=AXRYRYVKAWYZBR-GASGPIRDSA-N

InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C38H52N6O7
Molecular Weight	704.8555
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21567_reyataz_lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/15585441

Atazanavir is the first once-daily protease inhibitor for the treatment of human immunodeficiency virus type 1 infection and should be used only in combination therapy, as part of a highly active antiretroviral therapy (HAART) regimen. In addition to being the most potent protease inhibitor in vitro, atazanavir has a distinct cross-resistance profile that does not confer resistance to other protease inhibitors. However, resistance to other protease inhibitors often confers clinically relevant resistance to atazanavir.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus type 1 protease 35 Target ID: CHEMBL243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18006837	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 151 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21567_reyataz_lbl.pdf	Curative		Approved 8429	REYATAZ Approved Use REYATAZ® (atazanavir sulfate) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from controlled studies of 96 weeks duration in antiretroviral-naive and 48 weeks duration in antiretroviral-treatment-experienced adult and pediatric patients at least 6 years of age. The following points should be considered when initiating therapy with REYATAZ: In Study AI424-045, REYATAZ/ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in HIV RNA level. This study was not large enough to reach a definitive conclusion that REYATAZ/ritonavir and lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the HIV RNA lower limit of detection [see Clinical Studies (14.2) Launch Date 1.05606722E12

C_max

Value	Dose	Co-administered	Analyte	Population
4422 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: RITONAVIR	RITONAVIR	ATAZANAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
6129 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: RITONAVIR	RITONAVIR	ATAZANAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
2298 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ATAZANAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
5199 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ATAZANAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
46073 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: RITONAVIR	RITONAVIR	ATAZANAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
57039 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: RITONAVIR	RITONAVIR	ATAZANAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
14874 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ATAZANAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
28132 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ATAZANAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
8.6 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: RITONAVIR	RITONAVIR	ATAZANAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
18.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: RITONAVIR	RITONAVIR	ATAZANAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
6.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ATAZANAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
7.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ATAZANAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
14% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ATAZANAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED

Doses

Dose	Population	Adverse events
30 g single, oral Overdose Dose: 30 g Route: oral Route: single Dose: 30 g Sources: https://pubmed.ncbi.nlm.nih.gov/29706057/	unhealthy, 40 years n = 1 Health Status: unhealthy Condition: human immunodeficiency virus Age Group: 40 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29706057/	Other AEs: Monomorphic ventricular tachycardia... Other AEs: Monomorphic ventricular tachycardia Sources: https://pubmed.ncbi.nlm.nih.gov/29706057/
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15156449/	unhealthy, adult Health Status: unhealthy Condition: human immunodeficiency virus Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156449/	Disc. AE: Jaundice... Other AEs: Blood bilirubin indirect... AEs leading to discontinuation/dose reduction: Jaundice (7%) Other AEs: Blood bilirubin indirect (33%) Sources: https://pubmed.ncbi.nlm.nih.gov/15156449/

AEs

AE	Significance	Dose	Population
Monomorphic ventricular tachycardia		30 g single, oral Overdose Dose: 30 g Route: oral Route: single Dose: 30 g Sources: https://pubmed.ncbi.nlm.nih.gov/29706057/	unhealthy, 40 years n = 1 Health Status: unhealthy Condition: human immunodeficiency virus Age Group: 40 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29706057/
Blood bilirubin indirect	33%	400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15156449/	unhealthy, adult Health Status: unhealthy Condition: human immunodeficiency virus Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156449/
Jaundice	7% Disc. AE	400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15156449/	unhealthy, adult Health Status: unhealthy Condition: human immunodeficiency virus Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156449/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	substrate 1037 inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882 CYP3A4/5 278 CYP4A9/11 37 UGT1A1 204 P-gp 1461 OATP1B1 788 OATP1B3 706 BCRP 699	CYP1A2 1054 CYP2A6 543 CYP2B6 664 CYP2E1 667 CYP2C19 991 P-gp 1537

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28.0	no
CYP4A9/11 37	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28.0	no
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28.0	weak [IC50 29 uM]
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/20102298/	yes [IC50 1.7 uM]
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/20102298/	yes [IC50 3 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28.0	yes [IC50 4.9 uM]	BMS-551160 2
BCRP 773	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/20102298/	yes [IC50 69.1 uM]
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28.0	yes [Ki 12.1 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28.0	yes [Ki 12.7 uM]
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28,32	yes [Ki 2.35 uM]		yes (co-administration study) Comment: competitive and mechanism-based inhibition; administration with clarithromycin increased clarithromycin AUC by 94% and reduced 14-OH clarithromycin by 70; atazanavir increased diltiazem concentration by ~100%; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28,32
UGT1A1 254	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28.0	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=28 Page: 28.0	likely
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=27 Page: 27.0	not significant
CYP2A6 543	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=27 Page: 27.0	not significant
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=27 Page: 27.0	not significant
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=27 Page: 27.0	not significant
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=27 Page: 27.0	not significant
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=27 Page: 27.0	not significant
CYP2E1 667	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=27 Page: 27.0	not significant
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=27 Page: 27,29	yes	yes (co-administration study) Comment: 100% and 71% inhibition of ketonconazole and troleandomycin, respectively; administration with ritonavir increased atazanavir Cmax, AUC, and Cmin by 17%, 103%, and 671%, respectively; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf#page=27 Page: 27,29

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_Pharmr_P1A.pdf#page=7 Page: 7.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:37924	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:37924
MolPort	MolPort-003-986-575	https://www.molport.com/shop/molecule-link/MolPort-003-986-575
ZINC	ZINC000003941496	http://zinc15.docking.org/substances/ZINC000003941496
eMolecules	32176608	https://www.emolecules.com/cgi-bin/more?vid=32176608

PubMed

Title	Date	PubMed
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.	2000 Aug	10898681
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.	2000 Sep	10952574
Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.	2001 Apr 1	11237841
BMS-232632 (Novartis/Bristol-Myers Squibb).	2001 Mar	11575702
Gateways to Clinical Trials.	2002 Apr	12087878
[Simple, safe and effective. New protease inhibitor means progress].	2002 Dec 5	12577744
Promising new agents on the horizon.	2002 Mar	12141239
Atazanavir demonstrates antiviral efficacy and a favorable lipid profile at 48 weeks.	2002 Mar-Apr	11936070
Gateways to clinical trials.	2002 Nov	12616707
Gateways to clinical trials.	2002 Oct	12500432
[Antiretroviral therapy 2003. The current status].	2003 Apr 28	15011574
[New protease inhibitor against HIV. Viral load decreases--without lipid increase].	2003 Aug 21	14526586
Anti-HIV drug updates--three drugs on the near horizon.	2003 Jan	12647672
Drug profile: atazanavir (Reyataz, ATV).	2003 Jul	14696562
Atazanavir: clinical use.	2003 Jul	14696561
Atazanavir gets FDA Advisory Committee's thumbs-up.	2003 Jun	12951939
Gateways to clinical trials. March 2003.	2003 Mar	12731460
Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction.	2003 May 25	12705978
Gateways to clinical trials.	2003 Oct	14671684
FDA notifications. Reyataz is approved for HIV treatment.	2003 Sep	14686309
BMS issues PK notice regarding ATV + TDF.	2003 Sep	14672069
[Atazanavir--first protease inhibitor for one dose administration].	2003 Sep 26	14565208
[Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].	2004 Apr 26	15373065
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.	2004 Jun 1	15167287
Atazanavir: new option for treatment of HIV infection.	2004 Jun 1	15156449
Kinetic and thermodynamic characterization of HIV-1 protease inhibitors.	2004 Mar-Apr	15027031
Gateways to clinical trials.	2004 May	15319808
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.	2004 Oct 15	15358304
HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.	2004 Sep	15183346

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose of REYATAZ ((atazanavir sulfate) capsules) is 400 mg (two 200-mg capsules) once daily taken with food. When coadministered with efavirenz, it is recommended that REYATAZ 300 mg and ritonavir 100 mg be given with efavirenz 600 mg (all as a single daily dose with food). REYATAZ without ritonavir should not be coadministered with efavirenz. When coadministered with didanosine buffered formulations, 589 REYATAZ should be given (with food) 2 hours before or 1 hour after didanosine.

Route of Administration: Oral

In Vitro Use Guide

It was investigated the effect of atazanavir on P-glycoprotein (P-gp) expression and activity, as well as its inhibitory potency against CYP3A activity. Induction of P-gp activity and expression was studied using LS180V cells. P-gp inhibition was studied using both LS180V cells and Caco-2 cells. Extended (3-day) exposure of LS180V cells to 30 microM atazanavir caused a 2.5-fold increase in immunoreactive P-gp expression as well as a concentration-dependent decrease of intracellular Rh123 to a mean 45% (S.D. 5.2%) of control. Acute exposure (2 h) of LS180V cells to atazanavir increased intracellular Rh123 concentrations up to 300% of control at 100 microM atazanavir. At 30 microM and above, acute atazanavir exposure reversed P-gp induction caused by 3-day pretreatment with 10 microM ritonavir. P-gp inhibition was also observed in Caco-2 cells, causing an effect comparable to that observed for the known P-gp inhibitor verapamil (50% of control). In HLM, atazanavir was an inhibitor of triazolam hydroxylation, with inhibitory potency greatly increased by preincubation. IC50 values with and without preincubation were 0.31 microM (S.D. 0.13) and 5.7 microM (S.D. 4.1), respectively.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 15:48:40 UTC 2023` Edited by `admin` on `Sat Dec 16 15:48:40 UTC 2023`
Record UNII	QZU4H47A3S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ATAZANAVIR

Official Name

English

atazanavir [INN]

Common Name

English

CGP-73547

Code

English

BMS-232632

Code

English

2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-, 1,14-dimethyl ester, (3S,8S,9S,12S)-

Systematic Name

English

ATAZANAVIR [VANDF]

Common Name

English

ATAZANAVIR [MI]

Common Name

English

DIMETHYL (3S,8S,9S,12S)-9-BENZYL-3,12,DI-TERT-BUTYL-8-HYDROXY-4,11-DIOXO-6-(P-2-PYRIDYLBENZYL)-2,5,6,10,13-PENTAAZATETRADECANEDIOATE

Common Name

English

ATAZANAVIR [HSDB]

Common Name

English

Atazanavir [WHO-DD]

Common Name

English

1,14-Dimethyl (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

J05AR15